Parabilis Medicines (PBLS) investor relations material

Company overview and business model

• Clinical-stage biopharmaceutical company developing Helicon peptides to target historically undruggable intracellular proteins implicated in human disease.

• Lead candidate zolucatetide targets the b-catenin:TCF interaction in the Wnt/b-catenin pathway, a key driver in multiple cancers.

• Proprietary Helicon platform integrates AI-driven design, high-throughput synthesis, and experimental screening to generate and optimize drug candidates.

• Pipeline includes programs for desmoid tumors, FAP, HCC, rare tumors, CRC, and prostate cancer (ERG and ARON degraders).

• Strategic collaborations, including with Regeneron, expand platform reach and support development of Antibody-Helicon Conjugates.

Financial performance and metrics

• Net losses of $117.9M (2024) and $145.9M (2025); accumulated deficit of $586.8M as of March 31, 2026.

• Research and development expenses: $100.8M (2024), $125.6M (2025); general and administrative expenses: $25.3M (2024), $26.5M (2025).

• Cash and cash equivalents of $329.0M as of March 31, 2026; pro forma as adjusted cash post-IPO and private placement estimated at $957.1M.

• No product revenue to date; operations funded by equity, convertible preferred stock, SAFE, and collaboration payments.

Use of proceeds and capital allocation

• Estimated net proceeds of $553.1M from IPO and $75.0M from concurrent private placement with Regeneron.

• Proceeds allocated to clinical development of zolucatetide in desmoid tumors and other indications, advancement of pipeline programs, Helicon platform evolution, and general corporate purposes.

• Funds expected to support operations into the second half of 2029, but additional capital will be required for future operations and commercialization.